Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR100 Injection in Knee Osteoarthritis
NCT06049342Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of NCR100 in knee osteoarthritis (OA), sponsored by Nuwacell Biotechnologies. Primary endpoints: Adverse Event (AE) or Serious Adverse Event (SAE) at Week 4 and Dose-Limiting Toxicity. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
NCR100
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06049342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049342.